Vaccine maker Novavax has said its shot was highly effective against Covid-19 and also protected against variants in a large, late-stage study in the US and Mexico.
The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
The company says it plans to seek authorisation for the jabs in the US, Europe and elsewhere by the end of September and be able to produce up to 100 million doses a month by then.
“Many of our first doses will go to ... low and middle-income countries, and that was the goal to begin with,” Novavax chief executive Stanley Erck said today.
Less than 1 per cent of people in the developing world have had one Covid-19 vaccine dose, according to Our World In Data.
The study undertaken by the company involved nearly 30,000 people aged 18 and above in the US and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest got dummy shots.
There were 77 cases of Covid-19 in the group that got the vaccine and the rest were in volunteers who received dummy shots.
None in the vaccine group had moderate or severe disease, compared to 14 in the placebo group.
More to follow...
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.